Category: Journal

Posted on

jhc2025v9i1s4

Original Article

Expression of P53 in Clinically Diagnosed Solitary Thyroid Nodules

 *Ripa SP,1 Shilpi HK,2 Begum S3

 

  1. *Dr. Sabera Pervin Ripa, Assistant Professor, Department of Pathology, United Medical College, Shatarkul, Dhaka. dr.saberapervin@gmail.com.
  2. Harunur Rashid Khan Shilpi, Professor and ex-Head, Department of Pathology, Sir Salimullah Medical College, Dhaka.
  3. Shahnaj Begum, Professor and Head, Department of Pathology, Sir Salimullah Medical College, Dhaka.

 

*For correspondence

Abstract

Background: Solitary thyroid nodule has provoked increased concern owing to higher incidence of malignancy in it compared to multinodular goiter.Expression of p53 in solitary thyroid nodules has a significant impact on early diagnosis and better treatment strategy of thyroid carcinoma.

Method: Total 40 cases of solitary thyroid nodules were evaluated by immunohistochemical staining for mutant p53 expression. The study was performed in Sir Salimullah Medical College, Dhaka (from January, 2019 to December, 2020). Statistical analyses were carried out by using SPSS version 22 for Windows. A descriptive analysis was performed for all data.

Results: In this study, the mean age was 33.38 ± 13.11 and male to female ratio was 1:9. p53 expression was observed to be found more in relatively smaller tumor and most of the  differentiated tumors. Among malignant lesions, the predominant histologic type was papillary thyroid carcinoma (85%) including follicular variant and usual type. All carcinomas (100%) were well differentiated. Most of malignant lesions (92.6%) showed positive p53 expression.

Conclusion: Patients with p53 expression are related to malignant thyroid nodules. So, p53 immunoexpression is an important genetic marker for differentiating benign and malignant thyroid nodules.

 

[Journal of Histopathology and Cytopathology, 2025 Jan; 9 (1):20-29]

DOI: https://www.doi.org/10.69950/jhc2025v9i1s4

 

Keywords: Solitary thyroid nodule, p53

Posted on

jhc2025v9i1s3

Original Article

Expression of Estrogen Receptor and Progesterone Receptor in Malignant Epithelial Ovarian Tumors

*Shams S,1 Das R,2 Saha S3

  1. * Sifat Shams, Medical Officer, Department of Neuropathology, National Institute of Neurosciences and Hospital, Dhaka, Bangladesh. sifatshams24@gmail.com.
  2. Reba Das, Assistant Professor, Department of Pathology, Sathkhira Medical College Hospital, Sathkhira, Bangladesh
  3. Shawni Saha, Assistant Professor, Department of Pathology, Shaheed Suhrawardy Medical College Hospital, Bangladesh

*For correspondence

Abstract

Background: Malignant epithelial ovarian tumors are a significant cause of cancer-related deaths in women. The expression of estrogen and progesterone receptors (ER and PR) in these tumors has been studied extensively, as they play a critical role in the pathogenesis and treatment of ovarian cancer. ER and PR expression levels in ovarian tumors can impact treatment decisions and patient outcomes. Therefore, understanding the frequency and distribution of ER and PR expression in different types of ovarian tumors is crucial in improving patient care.

Method: This cross-sectional observational study was conducted at the Department of Pathology, Sir Salimullah Medical College and Mitford Hospital, Dhaka, Bangladesh. The study duration was 2 years, from January 2018 to December 2019. During this period, a total of 45 adult female patients with histopathologically diagnosed malignant epithelial ovarian tumors by H&E staging were selected for the study.

Results: In this study, the majority of participants were aged 41-60 years and reported irregular menstrual cycles or being post-menopausal. Most were nulliparous, and the mean CA125 level was 149.51. Serous cystadenocarcinoma was the most common diagnosis (68.89%). ER was positive in 51.11% of cases, with a higher proportion in serous cystadenocarcinoma (64.52%) compared to mucinous cystadenocarcinoma. PR was positive in 80% of cases, with the highest proportion in endometrioid carcinoma (50%). ER expression was significantly higher in serous tumors compared to non-serous tumors (p=0.002), but the association between tumor type and PR expression was not significant (p=0.192).

Conclusion: The study found that the majority of participants were aged 41-60 years, had irregular menstrual cycles, or were post-menopausal. Serous cystadenocarcinoma was the most common diagnosis. A significant difference in ER positivity was observed between serous and mucinous cystadenocarcinoma, as well as other subtypes. PR positivity was observed in the majority of participants, but no significant association was observed with histopathological subtypes or serous types.

[Journal of Histopathology and Cytopathology, 2025 Jan; 9 (1):10-19]

DOI: https://www.doi.org/10.69950/jhc2025v9i1s3

 Keywords:  Estrogen, Progesterone, Cancer, Carcinoma, Ovarian, Malignant

Posted on

jhc2025v9i1s2

Original Article

Association of E-cadherin Expression with Histopathological Grades and Clinical Stages of Laryngeal Squamous Cell Carcinoma

*Tayeb M,1Mimi SA,2 Kamal MS,3 Snigdha SS4

  1. *Dr. Mohammad Tayeb, MD (Pathology), Assistant Professor, Department of Pathology, Jahurul Islam Medical College. tmohammad75@yahoo.com
  2. Professor Dr. Shamim Akhter Mimi, M. Phil (Pathology), Professor and Head, Department of Pathology, Sylhet MAG Osmani Medical College.
  3. Mohammad Shah Kamal, FCPS (ENT), Associate Professor, Department of Otorhinology & Head-Neck Surgery, Sylhet MAG Osmani Medical College.
  4. Shyla Sharmin Snigdha, MD (Pathology),Assistant professor, Department of Pathology, Zainul Haque Sikder Women’s Medical College.

*For correspondence

Abstract
Background: E-cadherin gene plays an important role in the carcinogenesis of laryngeal squamous cell carcinoma (LSCC). This study aimed to evaluate the immunohistochemical expression of E-cadherin in different grades and clinical stages of LSCC and to determine the association of E-cadherin with clinical stages and histopathological grades.
Methods: This cross-sectional study was conducted in the Department of Pathology, Sylhet MAG Osmani Medical College, from March 2021 to January 2023. Immunohistochemistry was performed in 50 histopathologically diagnosed cases of LSCC using a commercially available anti-E-cadherin antibody. The total score of immunoreaction was calculated by multiplying the expression score and intensity score.
Results: The mean age of the LSCC patients was 62.8 years, and 66% were male. Grade I is the most frequent histopathological grade (48%), followed by grade II (42%) and grade III (10%). The most frequent clinical T stage was T3 (56%), and the N stage was N2 (58.06%). E-cadherin expression was positive in 72% of cases; the rest, 28%, showed reduced expression. A significant association was found between E-cadherin expression with histopathological grades (p=0.007) and clinical N stage (p=0.009) but not significant with clinical T stage (p=0.502), anatomic site (P=0.132), and the habit of smoking (0.276).

Conclusion: LSCC patients with reduced E-cadherin expression are at the risk of high-grade carcinoma and nodal metastasis. So, the expression of E-cadherin in pre-treatment biopsy samples can be utilized as one of the prognostic factors and advocated to anti-E-cadherin targeted therapy in LSCC.

[Journal of Histopathology and Cytopathology, 2025 Jan; 9 (1):3-9]

Keywords: E-cadherin, Expression, Immunohistochemistry, laryngeal squamous cell carcinoma.

DOI: https://www.doi.org/10.69950/jhc2025v9i1s2